CD40 ligand-modified CAR T cells displayed superior antitumor efficacy, promoted upregulation of co-stimulatory markers CD80 and CD86 on CD40+ lymphoma cells, educated antigen-presenting cells, enhanced recruitment of immune effectors, and mobilized specific tumor-recognizing T cells without outward signs of toxicity (96). This evidence concerns the gene CD86 and neoplasm.